Brief: US FDA Grants Accelerated Approval To Bayer's Hyrnuo As First-Line Targeted Therapy For Patients With Her2-Mutated Non-Small Cell Lung Cancer
10/09/2026 03:23
BRIEF-US FDA Grants Accelerated Approval To Bayer's Hyrnuo As First-Line Targeted Therapy For Patients With Her2-Mutated Non-Small Cell Lung Cancer Sept 9 (Reuters) - Bayer AG BAYGn.DE:
U.S. FDA GRANTS ACCELERATED APPROVAL TO BAYER’S HYRNUO® (SEVABERTINIB) AS A FIRST-LINE TARGETED THERAPY FOR PATIENTS WITH HER2-MUTATED NON-SMALL CELL LUNG CANCER
Source text: ID:nBw23q5Lqa
Further company coverage: [BAYGn.DE]
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bayer AG
See all newsBrief: Bayer Says Finerenone Slowed Kidney Decline In CKD
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant
Deutsche Bank AG FF - Post Stabilisation Notice -Bayer EUR 30NC6 & 30NC9
Brief: Bayer To Present New Finerenone Data Across Chronic Kidney Disease With And Without Diabetes At Asn Kidney Week 2026
Brief: FDA Approves Once-Weekly Generic Hormone Therapy Patch For Women